Home > Healthcare > Pharmaceuticals > Finished Drug Form > progesterone market
Get a free sample of Progesterone Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Progesterone Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The progesterone industry is characterized by diverse players competing in the industry. Eli Lily & Company, Glenmark Pharmaceuticals Limited, Novo Nordisk, and Alkem Laboratories Limited, account for significant market share. These prominent players adopt a combination of strategic initiatives such as collaborations & partnerships, global expansion strategies, research and development, product diversification, and regulatory compliance to maintain a competitive edge in the market.
The major players operating in the progesterone industry are as mentioned below:
Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Cadila Pharmaceuticals, Cipla Inc., Estrellas Life Sciences Private Limited., Eli Lily & Company, Glenmark Pharmaceuticals Ltd., Insud Pharma S.L.U., Lupin, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
North America market share was 39.2% of the revenue share in 2023, due to the region's advanced healthcare infrastructure, extensive R&D initiatives, and the widespread adoption of progesterone-based therapies for various medical conditions.
The natural segment dominated the market with 58.2% share in 2023, because of its bio-identical nature that closely mimics the progesterone produced by the human body, making it a preferred choice for many patients seeking hormone replacement therapy.
The market size of progesterone reached USD 1.3 billion in 2023 and is set to record 12.7% CAGR between 2024 and 2032, attributed to the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis.